WESPAC Advisors SoCal LLC Takes Position in BeOne Medicines Ltd. – Sponsored ADR $ONC

WESPAC Advisors SoCal LLC acquired a new position in shares of BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) during the third quarter, HoldingsChannel reports. The firm acquired 3,115 shares of the company’s stock, valued at approximately $1,061,000.

Other hedge funds also recently made changes to their positions in the company. Anchor Investment Management LLC acquired a new position in shares of BeOne Medicines during the second quarter worth $26,000. Caitong International Asset Management Co. Ltd purchased a new stake in BeOne Medicines in the 2nd quarter worth approximately $28,000. Daiwa Securities Group Inc. bought a new position in shares of BeOne Medicines during the second quarter valued at $35,000. Farther Finance Advisors LLC bought a new position in BeOne Medicines in the second quarter valued at about $39,000. Finally, Signaturefd LLC bought a new position in shares of BeOne Medicines during the second quarter worth $49,000. 48.55% of the stock is owned by institutional investors.

BeOne Medicines Price Performance

Shares of BeOne Medicines stock opened at $311.02 on Monday. The business has a 50-day moving average price of $326.62 and a 200 day moving average price of $311.48. The company has a quick ratio of 2.17, a current ratio of 2.39 and a debt-to-equity ratio of 0.03. The firm has a market cap of $34.11 billion, a PE ratio of 609.84 and a beta of 0.47. BeOne Medicines Ltd. – Sponsored ADR has a twelve month low of $172.67 and a twelve month high of $385.22.

Insider Activity

In other BeOne Medicines news, CEO John Oyler sold 24,369 shares of the business’s stock in a transaction dated Tuesday, December 16th. The shares were sold at an average price of $302.87, for a total value of $7,380,639.03. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, SVP Chan Henry Lee sold 332 shares of the business’s stock in a transaction that occurred on Thursday, December 11th. The shares were sold at an average price of $325.00, for a total value of $107,900.00. The disclosure for this sale is available in the SEC filing. Insiders sold 138,617 shares of company stock worth $44,632,898 over the last three months. Insiders own 6.62% of the company’s stock.

Analyst Upgrades and Downgrades

ONC has been the subject of several research analyst reports. Jefferies Financial Group restated a “buy” rating and issued a $420.00 price objective on shares of BeOne Medicines in a research note on Monday, November 17th. Morgan Stanley lifted their price objective on shares of BeOne Medicines from $350.00 to $383.00 and gave the company an “overweight” rating in a research note on Monday, October 20th. JPMorgan Chase & Co. increased their price target on BeOne Medicines from $345.00 to $385.00 and gave the company an “overweight” rating in a research report on Wednesday, October 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of BeOne Medicines in a report on Wednesday, October 8th. Finally, Truist Financial set a $400.00 target price on BeOne Medicines in a report on Monday, November 24th. Twelve research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $365.79.

BeOne Medicines Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.